Lysando Innovations Lab GmbH Lysando Innovations Lab GmbH Regensburg

Lysando AG created the Artilysin® platform technology to fight multidrug-resistant bacteria in various fields across different industries. Artilysin®s are muralytic proteins which are active on gram-positive and gram-negative target bacteria. The technology is continually developed to meet the expectations of our customers and the addressed markets.